Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have
entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the …

Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs
designed to exploit synthetic lethality, and were first introduced as a cancer-targeting …

Introduction Poly (ADP-ribose) polymerase (PARP) inhibitors are being developed in
maintenance and recurrence treatment settings of epithelial ovarian cancers (EOCs) with …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic
management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient …

The use of poly (ADP-ribose) polymerase (PARP) inhibition is transforming care for the
treatment of ovarian cancer, with three different PARP inhibitors (PARPi) gaining US Food …

Background Despite standard treatment for epithelial ovarian cancer (EOC), that involves
cytoreductive surgery followed by platinum-based chemotherapy, and initial high response …

Opinion statement Poly-ADP-ribose polymerase inhibitors (PARPi) are a class of anti-cancer
drugs that target DNA repair pathways and have shown promising efficacy in patients with …

Novel poly-ADP-ribose polymerase inhibitor combination strat... : Current Opinion in
Obstetrics and Gynecology Novel poly-ADP-ribose polymerase inhibitor combination …

The treatment of ovarian cancer has remained a clinical challenge despite high rates of
initial response to platinum-based chemotherapy. Patients are generally diagnosed at an …

Simple Summary Poly (ADP-ribose) polymerase (PARP) inhibitors have become an
essential part of the anticancer armamentarium in ovarian cancer. As maintenence therapy …